Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease

Fatty liver protection trial by telmisartan or losartan study (FANTASY)

Takumi Hirata, Kengo Tomita, Toshihide Kawai, Hirokazu Yokoyama, Akira Shimada, Masahiro Kikuchi, Hiroshi Hirose, Hirotoshi Ebinuma, Junichiro Irie, Keisuke Ojiro, Yoichi Oikawa, Hidetsugu Saito, Hiroshi Itoh, Toshifumi Hibi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan. Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n = 12) or losartan at a dose of 50 mg once a day (n = 7) for 12 months. Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months. Results. The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87 ± 0.26 to 0.59 ± 0.22 mEq/L (mean ± SD), P = 0.005) and a significant increase in L/S ratio (P = 0.049) evaluated by CT scan, while these parameters were not changed in the losartan group. Conclusion. Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver.

Original languageEnglish
Article number587140
JournalInternational Journal of Endocrinology
Volume2013
DOIs
Publication statusPublished - 2013

Fingerprint

Losartan
Fatty Liver
Type 2 Diabetes Mellitus
Liver
Therapeutics
Spleen
Group Psychotherapy
Lipid Metabolism
Nonesterified Fatty Acids
Insulin Resistance
telmisartan
Non-alcoholic Fatty Liver Disease
Adipose Tissue
Biomarkers
Fats
Enzymes
Serum

ASJC Scopus subject areas

  • Endocrine and Autonomic Systems
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease : Fatty liver protection trial by telmisartan or losartan study (FANTASY). / Hirata, Takumi; Tomita, Kengo; Kawai, Toshihide; Yokoyama, Hirokazu; Shimada, Akira; Kikuchi, Masahiro; Hirose, Hiroshi; Ebinuma, Hirotoshi; Irie, Junichiro; Ojiro, Keisuke; Oikawa, Yoichi; Saito, Hidetsugu; Itoh, Hiroshi; Hibi, Toshifumi.

In: International Journal of Endocrinology, Vol. 2013, 587140, 2013.

Research output: Contribution to journalArticle

@article{dd8ab003777744a4a9d3ae04c669b758,
title = "Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty liver protection trial by telmisartan or losartan study (FANTASY)",
abstract = "Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan. Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n = 12) or losartan at a dose of 50 mg once a day (n = 7) for 12 months. Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months. Results. The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87 ± 0.26 to 0.59 ± 0.22 mEq/L (mean ± SD), P = 0.005) and a significant increase in L/S ratio (P = 0.049) evaluated by CT scan, while these parameters were not changed in the losartan group. Conclusion. Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver.",
author = "Takumi Hirata and Kengo Tomita and Toshihide Kawai and Hirokazu Yokoyama and Akira Shimada and Masahiro Kikuchi and Hiroshi Hirose and Hirotoshi Ebinuma and Junichiro Irie and Keisuke Ojiro and Yoichi Oikawa and Hidetsugu Saito and Hiroshi Itoh and Toshifumi Hibi",
year = "2013",
doi = "10.1155/2013/587140",
language = "English",
volume = "2013",
journal = "International Journal of Endocrinology",
issn = "1687-8337",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease

T2 - Fatty liver protection trial by telmisartan or losartan study (FANTASY)

AU - Hirata, Takumi

AU - Tomita, Kengo

AU - Kawai, Toshihide

AU - Yokoyama, Hirokazu

AU - Shimada, Akira

AU - Kikuchi, Masahiro

AU - Hirose, Hiroshi

AU - Ebinuma, Hirotoshi

AU - Irie, Junichiro

AU - Ojiro, Keisuke

AU - Oikawa, Yoichi

AU - Saito, Hidetsugu

AU - Itoh, Hiroshi

AU - Hibi, Toshifumi

PY - 2013

Y1 - 2013

N2 - Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan. Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n = 12) or losartan at a dose of 50 mg once a day (n = 7) for 12 months. Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months. Results. The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87 ± 0.26 to 0.59 ± 0.22 mEq/L (mean ± SD), P = 0.005) and a significant increase in L/S ratio (P = 0.049) evaluated by CT scan, while these parameters were not changed in the losartan group. Conclusion. Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver.

AB - Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy with telmisartan or losartan. Nineteen hypertensive NAFLD patients with type 2 diabetes were randomly assigned to receive telmisartan at a dose of 20 mg once a day (n = 12) or losartan at a dose of 50 mg once a day (n = 7) for 12 months. Body fat area as determined by CT scanning and hepatic fat content based on the liver-to-spleen (L/S) ratio, as well as several parameters of glycemic and lipid metabolism, were compared before and after 12 months. Results. The telmisartan group showed a significant decline in serum free fatty acid (FFA) level (from 0.87 ± 0.26 to 0.59 ± 0.22 mEq/L (mean ± SD), P = 0.005) and a significant increase in L/S ratio (P = 0.049) evaluated by CT scan, while these parameters were not changed in the losartan group. Conclusion. Although there was no significant difference in improvement in liver enzymes with telmisartan and losartan treatment in hypertensive NAFLD patients with type 2 diabetes after 12 months, it is suggested that telmisartan may exert beneficial effects by improving fatty liver.

UR - http://www.scopus.com/inward/record.url?scp=84884237337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884237337&partnerID=8YFLogxK

U2 - 10.1155/2013/587140

DO - 10.1155/2013/587140

M3 - Article

VL - 2013

JO - International Journal of Endocrinology

JF - International Journal of Endocrinology

SN - 1687-8337

M1 - 587140

ER -